Clearside Biomedical (CLSD) AI Stock Analysis

• Market Cap: $63.12M
• Dividend Yield: N/A
• Average Volume (3M): 326.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: -55.47%
• EPS Growth: 24.92%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 77,708,534
• 10 Day Avg. Volume: 203,715
• 30 Day Avg. Volume: 326,955
• PEG Ratio: <0.01
• Price to Book (P/B): 6.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.95
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 0.99
• Enterprise Value/Gross Profit: 6.08
• Enterprise Value/Ebitda: -0.23
• 1Y Price Target: $5.40
• Price Target Upside: 566.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 44 Neutral
• Price Target: $1.00 ▲(23.46%Upside)

The overall stock score is primarily impacted by Clearside Biomedical's poor financial performance, characterized by declining revenues, ongoing losses, and a weak balance sheet. Limited technical momentum and a negative valuation further weigh on the score, indicating high financial risk and limited attractiveness to investors.

Positive Factors

Product Differentiation

The key differentiator for CLS-AX is its flexible dosing schedule for every 3 to 6 months based on disease activity.

Regulatory Progress

Arctic Vision's New Drug Application for ARCATUS was accepted for review in China and approved in Australia and Singapore for the treatment of uveitic macular edema.

Valuation

CLSD is trading at a heavy discount compared to peers despite having a competitive Phase 3 ready asset.

Negative Factors

Capital Requirements

Clearside Biomedical Inc. needs to secure additional financing or enter into a partnership to advance the proposed phase 3 program.

Financial Performance

Net loss totaled $8.2M in search of funding for Phase 3 wet AMD program.

Investment Needs

The phase 3 trials are expected to require significant investment and could take 2 to 3 years to report results.

Clearside Biomedical Business Overview & Revenue Model

Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

How the Company Makes Money

Clearside Biomedical makes money primarily through the development and potential commercialization of its proprietary therapies for eye diseases. The company generates revenue through collaborative agreements, licensing arrangements, and milestone payments from partnerships with pharmaceutical companies. These partnerships often involve Clearside providing its SCS Microinjector™ technology to facilitate drug delivery. Additionally, the company may earn revenue from the eventual sale of approved therapies derived from its product pipeline, as well as from potential royalties on sales of partnered products.

Clearside Biomedical Financial Statement Overview

Summary

Clearside Biomedical's financials demonstrate significant challenges, including declining revenues leading to zero, persistent losses, negative stockholders' equity, and negative free cash flow. The company's reliance on external financing, coupled with high liabilities and leverage risks, presents substantial financial instability.

Income Statement

The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.

Cash Flow

The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.76M	1.66M	8.23M	1.33M	29.57M	7.89M
Gross Profit	3.37M	1.51M	7.87M	1.12M	29.40M	7.89M
EBITDA	-19.76M	-24.35M	-23.06M	-29.46M	-449.00K	-17.93M
Net Income	-30.81M	-34.35M	-32.48M	-34.07M	376.00K	-18.03M
Balance Sheet
Total Assets	19.67M	25.13M	34.02M	51.30M	42.90M	19.32M
Cash, Cash Equivalents and Short-Term Investments	13.63M	20.02M	28.92M	48.26M	30.44M	17.29M
Total Debt	619.00K	703.00K	43.00M	1.28M	675.00K	1.98M
Total Liabilities	65.58M	63.98M	49.93M	40.70M	4.93M	10.56M
Stockholders Equity	-45.91M	-38.85M	-15.91M	10.61M	37.98M	8.76M
Cash Flow
Free Cash Flow	-23.60M	-25.68M	-19.91M	-13.61M	-10.73M	-13.18M
Operating Cash Flow	-22.68M	-24.70M	-18.14M	-13.37M	-10.73M	-13.12M
Investing Cash Flow	-590.00K	-638.00K	-1.78M	-246.00K	0.00	-55.00K
Financing Cash Flow	1.54M	16.44M	414.00K	31.33M	23.78M	7.87M

Clearside Biomedical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Neutral. The current price of 0.81 is above the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.82, and below the 200-day MA of 0.97, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLSD.

Clearside Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
CLSD	44 Neutral	$63.12M	―	91.63%	―	-55.47%	24.92%
ADAG	44 Neutral	$87.15M	―	-55.14%	―	-99.43%	-69.40%
IVVD	44 Neutral	$88.18M	―	-122.69%	―	―	20.91%
ADVM	40 Neutral	$47.63M	―	-127.99%	―	―	37.54%
INZY	37 Underperform	$258.25M	―	-141.69%	―	―	-17.06%
JSPR	35 Underperform	$101.70M	―	-101.34%	―	―	21.40%

Clearside Biomedical Corporate Events

Clearside Biomedical Approves Share Increase at Annual Meeting

On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.